Kazia Therapeutics Limite... (KZIA)
NASDAQ: KZIA
· Real-Time Price · USD
9.20
-0.10 (-1.08%)
At close: Jun 16, 2025, 3:59 PM
8.98
-2.39%
Pre-market: Jun 17, 2025, 05:14 AM EDT
-1.08% (1D)
| Bid | 8.85 |
| Market Cap | 8.9M |
| Revenue (ttm) | 2.48M |
| Net Income (ttm) | -26.78M |
| EPS (ttm) | -29.09 |
| PE Ratio (ttm) | -0.32 |
| Forward PE | -0.78 |
| Analyst | Buy |
| Ask | 9.05 |
| Volume | 252,043 |
| Avg. Volume (20D) | 837,175 |
| Open | 9.25 |
| Previous Close | 9.30 |
| Day's Range | 8.83 - 10.00 |
| 52-Week Range | 2.86 - 79.00 |
| Beta | 2.48 |
About KZIA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KZIA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KZIA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 days ago
+81.37%
Kazia Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
+37.68%
Kazia Therapeutics shares are trading higher following regulatory approval and the launch of a clinical trial evaluating the combination of Paxalisib and immunotherapy in advanced breast cancer patients.
